SG11201907308UA - Pharmaceutical combination comprising ponesimod - Google Patents
Pharmaceutical combination comprising ponesimodInfo
- Publication number
- SG11201907308UA SG11201907308UA SG11201907308UA SG11201907308UA SG11201907308UA SG 11201907308U A SG11201907308U A SG 11201907308UA SG 11201907308U A SG11201907308U A SG 11201907308UA SG 11201907308U A SG11201907308U A SG 11201907308UA SG 11201907308U A SG11201907308U A SG 11201907308UA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- ponesimod
- allschwil
- pct
- teriflunomide
- Prior art date
Links
- 229950009275 ponesimod Drugs 0.000 title abstract 5
- LPAUOXUZGSBGDU-STDDISTJSA-N chembl1096146 Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=N/CCC)/S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-STDDISTJSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 3
- 102220240796 rs553605556 Human genes 0.000 abstract 3
- 229960000331 teriflunomide Drugs 0.000 abstract 3
- 239000004480 active ingredient Substances 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- UTNUDOFZCWSZMS-YFHOEESVSA-N teriflunomide Chemical compound C\C(O)=C(/C#N)C(=O)NC1=CC=C(C(F)(F)F)C=C1 UTNUDOFZCWSZMS-YFHOEESVSA-N 0.000 abstract 2
- LPAUOXUZGSBGDU-ULCCENQXSA-N (5z)-5-[[3-chloro-4-[(2r)-2,3-dihydroxypropoxy]phenyl]methylidene]-3-(2-methylphenyl)-2-propylimino-1,3-thiazolidin-4-one Chemical compound O=C1N(C=2C(=CC=CC=2)C)C(=NCCC)S\C1=C/C1=CC=C(OC[C@H](O)CO)C(Cl)=C1 LPAUOXUZGSBGDU-ULCCENQXSA-N 0.000 abstract 1
- GJPICJJJRGTNOD-UHFFFAOYSA-N bosentan Chemical compound COC1=CC=CC=C1OC(C(=NC(=N1)C=2N=CC=CN=2)OCCO)=C1NS(=O)(=O)C1=CC=C(C(C)(C)C)C=C1 GJPICJJJRGTNOD-UHFFFAOYSA-N 0.000 abstract 1
- 229960003065 bosentan Drugs 0.000 abstract 1
- 229960000681 leflunomide Drugs 0.000 abstract 1
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 abstract 1
- 230000008520 organization Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/275—Nitriles; Isonitriles
- A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/421—1,3-Oxazoles, e.g. pemoline, trimethadione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Pyrane Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP2017055994 | 2017-03-14 | ||
| PCT/EP2018/056185 WO2018167030A1 (fr) | 2017-03-14 | 2018-03-13 | Combinaison pharmaceutique comprenant du ponesimod |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907308UA true SG11201907308UA (en) | 2019-09-27 |
Family
ID=61655772
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907308UA SG11201907308UA (en) | 2017-03-14 | 2018-03-13 | Pharmaceutical combination comprising ponesimod |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US11723896B2 (fr) |
| EP (1) | EP3595657A1 (fr) |
| JP (3) | JP7281406B2 (fr) |
| KR (1) | KR102574562B1 (fr) |
| CN (1) | CN110381942B (fr) |
| AU (2) | AU2018233109B2 (fr) |
| BR (1) | BR112019018894A2 (fr) |
| CA (1) | CA3056301A1 (fr) |
| CL (1) | CL2019002525A1 (fr) |
| CO (1) | CO2019008510A2 (fr) |
| CR (1) | CR20190464A (fr) |
| DO (1) | DOP2019000257A (fr) |
| EA (1) | EA201992117A1 (fr) |
| EC (1) | ECSP19073317A (fr) |
| IL (1) | IL269239B2 (fr) |
| JO (1) | JOP20190207A1 (fr) |
| MA (1) | MA49822A (fr) |
| MX (1) | MX390941B (fr) |
| NI (1) | NI201900092A (fr) |
| PE (1) | PE20191489A1 (fr) |
| PH (1) | PH12019502110A1 (fr) |
| SG (1) | SG11201907308UA (fr) |
| UA (1) | UA125756C2 (fr) |
| WO (1) | WO2018167030A1 (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
| US11013723B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms of a thiazolidinone compound, compositions and methods of use thereof |
| US11014897B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Solid forms comprising a thiazolidinone compound, compositions and methods of use thereof |
| US11014940B1 (en) | 2018-10-16 | 2021-05-25 | Celgene Corporation | Thiazolidinone and oxazolidinone compounds and formulations |
| US11186556B1 (en) | 2018-10-16 | 2021-11-30 | Celgene Corporation | Salts of a thiazolidinone compound, solid forms, compositions and methods of use thereof |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL178596C (nl) | 1975-06-05 | 1986-04-16 | Hoechst Ag | Werkwijze voor het bereiden van een geneesmiddel met antiflogistische en/of analgetische werking, alsmede werkwijze voor het bereiden van daarin als geneeskrachtige verbindingen te gebruiken 5-methylisoxazool-4-carbonzuuraniliden. |
| DE2854439A1 (de) | 1978-12-16 | 1980-07-03 | Hoechst Ag | Ein isoxazolderivat, verfahren zu seiner herstellung, diese verbindung enthaltende mittel und verwendung |
| DE3534440A1 (de) | 1985-09-27 | 1987-04-02 | Hoechst Ag | Arzneimittel gegen chronische graft-versus-host-krankheiten sowie gegen autoimmunerkrankungen, insbesondere systemischen lupus erythematodes |
| US5268382A (en) | 1985-09-27 | 1993-12-07 | Hoechst Aktiengesellschaft | Medicaments to combat autoimmune diseases, in particular systemic lupus erythematosus |
| CZ20023024A3 (cs) * | 2000-02-15 | 2003-05-14 | Teva Pharmaceutical Industries Ltd. | Způsob syntézy leflunomidu |
| GB0123571D0 (en) * | 2001-04-05 | 2001-11-21 | Aventis Pharm Prod Inc | Use of (Z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating multiple sclerosis |
| EP1381356B1 (fr) * | 2001-04-05 | 2008-05-28 | Aventis Pharmaceuticals Inc. | Utilisation de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique-(4'-trifluoromethylphenyl)-amide pour le traitement de la sclerose en plaques |
| US6894184B2 (en) | 2003-03-18 | 2005-05-17 | Aventis Pharma Deutschland Gmbh | Process for preparing 2-cyano-3-hydroxy-N-(phenyl)but-2-enamides |
| USRE43833E1 (en) | 2003-11-21 | 2012-11-27 | Actelion Pharmaceuticals Ltd. | Thiazolidin-4-one derivatives |
| DK1689726T3 (da) | 2003-11-21 | 2010-12-06 | Actelion Pharmaceuticals Ltd | 5-(benz-(z)-yliden)-thiazolidin-4-on-derivater som immunsuppresserende midler |
| EP1804782A1 (fr) * | 2004-10-19 | 2007-07-11 | Aventis Pharmaceuticals Inc. | Emploi du (4'-trifluoromethylphenyl)amide de l'acide (z)-2-cyano-3-hydroxy-but-2-enoique dans le traitement d affections abdominales inflammatoires |
| DE102006017896A1 (de) | 2006-04-13 | 2007-10-25 | Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg | Leflunomid enthaltende pharmazeutische Zusammensetzungen |
| US8263780B2 (en) | 2006-11-23 | 2012-09-11 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| US8912340B2 (en) | 2006-11-23 | 2014-12-16 | Actelion Pharmaceuticals Ltd. | Process for the preparation of 2-imino-thiazolidin-4-one derivatives |
| CN101980704A (zh) | 2008-03-17 | 2011-02-23 | 埃科特莱茵药品有限公司 | 选择性s1p1受体激动剂的给药方案 |
| GB0819182D0 (en) | 2008-10-20 | 2008-11-26 | Actelion Pharmaceuticals Ltd | Crystalline forms |
| LT2477611T (lt) | 2009-09-18 | 2017-06-26 | Sanofi | (z)-2-ciano-3-hidroksi-but-2-enoinės rūgšties (4`-trifluormetilfenil)-amido pagerinto stabilumo tablečių kompozicijos |
| EP2598126A2 (fr) | 2010-07-30 | 2013-06-05 | Saint Louis University | Méthodes de traitement de la douleur |
| EP2600861A1 (fr) | 2010-08-02 | 2013-06-12 | Sanofi-Aventis U.S. LLC | Utilisation de tériflunomide dans le traitement de la sclérose en plaques |
| EP2692343A1 (fr) * | 2012-08-03 | 2014-02-05 | Forward Pharma A/S | Polythérapie pour le traitement de la sclérose en plaques |
| JP6322630B2 (ja) | 2012-08-17 | 2018-05-09 | アクテリオン ファーマシューティカルズ リミテッドＡｃｔｅｌｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｌｔｄ | （２Ｚ，５Ｚ）−５−（３−クロロ−４−（（Ｒ）−２，３−ジヒドロキシプロポキシ）ベンジリデン）−２−（プロピルイミノ）−３−（ｏ−トリル）チアゾリジン−４−オンの製造方法及び前記方法において使用される中間体 |
| WO2016079687A1 (fr) | 2014-11-18 | 2016-05-26 | Lupin Limited | Composition pharmaceutique orale de tériflunomide |
| MA41139A (fr) | 2014-12-11 | 2017-10-17 | Actelion Pharmaceuticals Ltd | Combinaison pharmaceutique comportant un agoniste sélectif du récepteur sip1 |
| DK3256125T3 (da) | 2014-12-11 | 2022-03-21 | Actelion Pharmaceuticals Ltd | Doseringsregimen for ponesimod, en selektiv s1p1-receptoragonist |
| CN107920991A (zh) | 2015-06-18 | 2018-04-17 | 马丁尼斯生物制药纳米技术公司 | 治疗炎性疾病或病状的组合物和方法 |
| JOP20190207A1 (ar) * | 2017-03-14 | 2019-09-10 | Actelion Pharmaceuticals Ltd | تركيبة صيدلانية تشتمل على بونيسيمود |
-
2017
- 2017-06-16 JO JOP/2019/0207A patent/JOP20190207A1/ar unknown
-
2018
- 2018-03-13 BR BR112019018894A patent/BR112019018894A2/pt not_active Application Discontinuation
- 2018-03-13 US US16/494,163 patent/US11723896B2/en active Active
- 2018-03-13 MX MX2019010874A patent/MX390941B/es unknown
- 2018-03-13 SG SG11201907308UA patent/SG11201907308UA/en unknown
- 2018-03-13 KR KR1020197026599A patent/KR102574562B1/ko active Active
- 2018-03-13 JP JP2019549459A patent/JP7281406B2/ja active Active
- 2018-03-13 AU AU2018233109A patent/AU2018233109B2/en active Active
- 2018-03-13 EP EP18711299.0A patent/EP3595657A1/fr active Pending
- 2018-03-13 WO PCT/EP2018/056185 patent/WO2018167030A1/fr not_active Ceased
- 2018-03-13 CR CR20190464A patent/CR20190464A/es unknown
- 2018-03-13 MA MA049822A patent/MA49822A/fr unknown
- 2018-03-13 EA EA201992117A patent/EA201992117A1/ru unknown
- 2018-03-13 CN CN201880017102.0A patent/CN110381942B/zh active Active
- 2018-03-13 UA UAA201910123A patent/UA125756C2/uk unknown
- 2018-03-13 PE PE2019001845A patent/PE20191489A1/es unknown
- 2018-03-13 CA CA3056301A patent/CA3056301A1/fr active Pending
-
2019
- 2019-08-05 CO CONC2019/0008510A patent/CO2019008510A2/es unknown
- 2019-09-03 CL CL2019002525A patent/CL2019002525A1/es unknown
- 2019-09-10 IL IL269239A patent/IL269239B2/en unknown
- 2019-09-11 NI NI201900092A patent/NI201900092A/es unknown
- 2019-09-13 PH PH12019502110A patent/PH12019502110A1/en unknown
- 2019-10-08 DO DO2019000257A patent/DOP2019000257A/es unknown
- 2019-10-10 EC ECSENADI201973317A patent/ECSP19073317A/es unknown
-
2022
- 2022-12-21 JP JP2022204487A patent/JP2023030091A/ja active Pending
-
2023
- 2023-06-27 US US18/341,853 patent/US20240139161A1/en active Pending
- 2023-11-29 AU AU2023274118A patent/AU2023274118B2/en active Active
-
2024
- 2024-04-18 JP JP2024067486A patent/JP2024096962A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201907308UA (en) | Pharmaceutical combination comprising ponesimod | |
| SG11201909011PA (en) | Niraparib compositions | |
| SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
| SG11201808713YA (en) | Ophthalmic compositions comprising levodopa, an antioxidant and an aqueous carrier | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201809082WA (en) | Nlrp3 modulators | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201900743UA (en) | Multiple function exercise device | |
| SG11201807827VA (en) | Process for the preparation of pegylated drug-linkers and intermediates thereof | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201809908TA (en) | Stabilized glycopeptide antibiotic formulations | |
| SG11201807784SA (en) | 3-desoxy derivative and pharmaceutical compositions thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201906383WA (en) | A layered medical data computer architecture |